Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes.
Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response.
Hanafi
Laïla-Aïcha
LA
Research Centre, Centre hospitalier de l'Université de Montréal (CRCHUM) - Hôpital Notre-Dame, Université de Montréal and Institut du Cancer de Montréal, Montréal, Québec, Canada.
Bolduc
Marilène
M
Gagné
Marie-Eve Laliberté
ME
Dufour
Florent
F
Langelier
Yves
Y
Boulassel
Mohammed-Rachid
MR
Routy
Jean-Pierre
JP
Leclerc
Denis
D
Lapointe
Réjean
R
D000595:Amino Acid Sequence; D017951:Antigen Presentation; D001402:B-Lymphocytes / Q000276:immunology; D019013:CD40 Antigens / Q000276:immunology; D036022:Capsid Proteins / Q000276:immunology; D049109:Cell Proliferation; D003001:Cloning, Molecular; D045142:Cross-Priming; D000939:Epitopes / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D017863:Potexvirus / Q000276:immunology*; D015202:Protein Engineering; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology
D019013:CD40 Antigens; D036022:Capsid Proteins; D000939:Epitopes